Roxane J Hillier1,2,3,4, Elvis Ojaimi1,2,5, David T Wong1,2, Michael Y K Mak6, Alan R Berger1,2, Radha P Kohly1,7, Peter J Kertes1,7, Farzin Forooghian8, Shelley R Boyd1,2, Kenneth Eng1,7, Filiberto Altomare1,2, Louis R Giavedoni1,2, Rosane Nisenbaum9, Rajeev H Muni1,2,10. 1. Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada. 2. Department of Ophthalmology, St. Michael's Hospital, Toronto, Ontario, Canada. 3. Newcastle Eye Centre, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom. 4. Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, United Kingdom. 5. Save Sight Institute, University of Sydney, Sydney, Australia. 6. Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. 7. The John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. 8. Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, British Columbia, Canada. 9. Centre for Research on Inner City Health, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada. 10. Kensington Vision and Research Centre, Toronto, Ontario, Canada.
Abstract
Importance: Variability in response to anti-vascular endothelial growth factor (VEGF) treatment in diabetic macular edema (DME) remains a significant clinical challenge. Biomarkers could help anticipate responses to anti-VEGF therapy. Objectives: To investigate aqueous humor cytokine level changes in response to intravitreal ranibizumab therapy for the management of DME, and to determine the association between baseline aqueous levels and anatomic response. Design, Setting, and Participants: In this prospective multicenter cohort study, 49 participants with diabetes mellitus complicated by center-involving DME, with a central subfield thickness of 310 μm or greater on spectral-domain optical coherence tomography (SD-OCT), were recruited from December 22, 2011, to June 13, 2013 and statistical analysis were performed from March 1, 2017, to June 1, 2017. A total of 48 participants proceeded to follow-up. Interventions: Participants received monthly injections of ranibizumab, 0.5 mg, for 3 months. Aqueous fluid for cytokine analysis was obtained at baseline and repeated at the 2-month visit. Multiplex immunoassay was carried out in duplicate for VEGF, placental growth factor, transforming growth factor beta 2, intercellular adhesion molecule 1 (ICAM-1), interleukin 6 (IL-6), IL-8, IL-10, vascular intercellular adhesion molecule, and monocyte chemoattractant protein 1. Main Outcomes and Measures: Baseline and 2-month change in aqueous cytokine levels, 3-month change in SD-OCT central subfield thickness and macular volume (MV), and the statistical association between baseline aqueous cytokine levels and these measures of anatomic response to ranibizumab in center-involving DME. Results: Among the 48 participants, the mean (SD) age was 61.9 (7.1) years and 36 participants (75.0%) were men. The following cytokines were lower at month 2 vs baseline: ICAM-1 (median change, -190.88; interquartile range [IQR], -634.20 to -26.54; P < .001), VEGF (median change, -639.45; IQR, -1040.61 to -502.61; P < .001), placental growth factor (median change, -1.31; IQR, -5.99 to -0.01; P < .001), IL-6 (median change, -38.61; IQR, -166.72 to -2.80; P < .001), and monocyte chemoattractant protein 1 (median change, -90.13; IQR, -382.74 to 109.47; P = .01). When controlling for age, foveal avascular zone size, and severity of retinopathy, multiple linear regression determined that increasing baseline aqueous ICAM-1 was associated with a favorable anatomic response, in terms of reduced SD-OCT MV at 3 months (every additional 100 pg/mL of baseline ICAM-1 was associated with a reduction of 0.0379 mm3; P = .01). Conversely, increasing baseline aqueous VEGF was associated with a less favorable SD-OCT MV response at 3 months (every additional 100 pg/mL of baseline VEGF was associated with an increase of 0.0731 mm3; P = .02) and was associated with lower odds of being a central subfield thickness responder (odds ratio, 0.868; 95% CI, 0.755-0.998). Conclusions and Relevance: Elevated aqueous ICAM-1 and reduced VEGF levels at baseline are associated with a favorable anatomic response to ranibizumab in DME, although there is not always direct correlation between anatomic and visual acuity response.
Importance: Variability in response to anti-vascular endothelial growth factor (VEGF) treatment in diabetic macular edema (DME) remains a significant clinical challenge. Biomarkers could help anticipate responses to anti-VEGF therapy. Objectives: To investigate aqueous humor cytokine level changes in response to intravitreal ranibizumab therapy for the management of DME, and to determine the association between baseline aqueous levels and anatomic response. Design, Setting, and Participants: In this prospective multicenter cohort study, 49 participants with diabetes mellitus complicated by center-involving DME, with a central subfield thickness of 310 μm or greater on spectral-domain optical coherence tomography (SD-OCT), were recruited from December 22, 2011, to June 13, 2013 and statistical analysis were performed from March 1, 2017, to June 1, 2017. A total of 48 participants proceeded to follow-up. Interventions: Participants received monthly injections of ranibizumab, 0.5 mg, for 3 months. Aqueous fluid for cytokine analysis was obtained at baseline and repeated at the 2-month visit. Multiplex immunoassay was carried out in duplicate for VEGF, placental growth factor, transforming growth factor beta 2, intercellular adhesion molecule 1 (ICAM-1), interleukin 6 (IL-6), IL-8, IL-10, vascular intercellular adhesion molecule, and monocyte chemoattractant protein 1. Main Outcomes and Measures: Baseline and 2-month change in aqueous cytokine levels, 3-month change in SD-OCT central subfield thickness and macular volume (MV), and the statistical association between baseline aqueous cytokine levels and these measures of anatomic response to ranibizumab in center-involving DME. Results: Among the 48 participants, the mean (SD) age was 61.9 (7.1) years and 36 participants (75.0%) were men. The following cytokines were lower at month 2 vs baseline: ICAM-1 (median change, -190.88; interquartile range [IQR], -634.20 to -26.54; P < .001), VEGF (median change, -639.45; IQR, -1040.61 to -502.61; P < .001), placental growth factor (median change, -1.31; IQR, -5.99 to -0.01; P < .001), IL-6 (median change, -38.61; IQR, -166.72 to -2.80; P < .001), and monocyte chemoattractant protein 1 (median change, -90.13; IQR, -382.74 to 109.47; P = .01). When controlling for age, foveal avascular zone size, and severity of retinopathy, multiple linear regression determined that increasing baseline aqueous ICAM-1 was associated with a favorable anatomic response, in terms of reduced SD-OCT MV at 3 months (every additional 100 pg/mL of baseline ICAM-1 was associated with a reduction of 0.0379 mm3; P = .01). Conversely, increasing baseline aqueous VEGF was associated with a less favorable SD-OCT MV response at 3 months (every additional 100 pg/mL of baseline VEGF was associated with an increase of 0.0731 mm3; P = .02) and was associated with lower odds of being a central subfield thickness responder (odds ratio, 0.868; 95% CI, 0.755-0.998). Conclusions and Relevance: Elevated aqueous ICAM-1 and reduced VEGF levels at baseline are associated with a favorable anatomic response to ranibizumab in DME, although there is not always direct correlation between anatomic and visual acuity response.
Authors: Jeffrey S Heier; Neil M Bressler; Robert L Avery; Sophie J Bakri; David S Boyer; David M Brown; Pravin U Dugel; K Bailey Freund; Adam R Glassman; Judy E Kim; Daniel F Martin; John S Pollack; Carl D Regillo; Philip J Rosenfeld; Andrew P Schachat; John A Wells Journal: JAMA Ophthalmol Date: 2016-01 Impact factor: 7.389
Authors: Roxane J Hillier; Elvis Ojaimi; David T Wong; Michael Y K Mak; Alan R Berger; Radha P Kohly; Peter J Kertes; Farzin Forooghian; Shelley R Boyd; Kenneth Eng; Filiberto Altomare; Louis R Giavedoni; Rosane Nisenbaum; Rajeev H Muni Journal: Retina Date: 2017-04 Impact factor: 4.256
Authors: K Miyamoto; S Khosrof; S E Bursell; R Rohan; T Murata; A C Clermont; L P Aiello; Y Ogura; A P Adamis Journal: Proc Natl Acad Sci U S A Date: 1999-09-14 Impact factor: 11.205
Authors: C P Wilkinson; Frederick L Ferris; Ronald E Klein; Paul P Lee; Carl David Agardh; Matthew Davis; Diana Dills; Anselm Kampik; R Pararajasegaram; Juan T Verdaguer Journal: Ophthalmology Date: 2003-09 Impact factor: 12.079
Authors: Quan Dong Nguyen; Syed Mahmood Shah; Jeffery S Heier; Diana V Do; Jennifer Lim; David Boyer; Prema Abraham; Peter A Campochiaro Journal: Ophthalmology Date: 2009-08-22 Impact factor: 12.079
Authors: Nicholas Papadopoulos; Joel Martin; Qin Ruan; Ashique Rafique; Michael P Rosconi; Ergang Shi; Erica A Pyles; George D Yancopoulos; Neil Stahl; Stanley J Wiegand Journal: Angiogenesis Date: 2012-06 Impact factor: 9.596
Authors: Devon H Ghodasra; Ryan Fante; Thomas W Gardner; Michael Langue; Leslie M Niziol; Cagri Besirli; Steven R Cohen; Vaidehi S Dedania; Hakan Demirci; Nieraj Jain; K Thiran Jayasundera; Mark W Johnson; Partho S Kalyani; Rajesh C Rao; David N Zacks; Jeffrey M Sundstrom Journal: Invest Ophthalmol Vis Sci Date: 2016-06-01 Impact factor: 4.799
Authors: Philipp K Roberts; Wolf-Dieter Vogl; Bianca S Gerendas; Adam R Glassman; Hrvoje Bogunovic; Lee M Jampol; Ursula M Schmidt-Erfurth Journal: JAMA Ophthalmol Date: 2020-09-01 Impact factor: 7.389
Authors: Yoshihiro Inamoto; Igor Petriček; Linda Burns; Saurabh Chhabra; Zachariah DeFilipp; Peiman Hematti; Alicia Rovó; Raquel Schears; Ami Shah; Vaibhav Agrawal; Aisha Ahmed; Ibrahim Ahmed; Asim Ali; Mahmoud Aljurf; Hassan Alkhateeb; Amer Beitinjaneh; Neel Bhatt; Dave Buchbinder; Michael Byrne; Natalie Callander; Kristina Fahnehjelm; Nosha Farhadfar; Robert Peter Gale; Siddhartha Ganguly; Shahrukh Hashmi; Gerhard C Hildebrandt; Erich Horn; Ann Jakubowski; Rammurti T Kamble; Jason Law; Catherine Lee; Sunita Nathan; Olaf Penack; Ravi Pingali; Pinki Prasad; Drazen Pulanic; Seth Rotz; Aditya Shreenivas; Amir Steinberg; Khalid Tabbara; André Tichelli; Baldeep Wirk; Jean Yared; Grzegorz W Basak; Minoo Battiwalla; Rafael Duarte; Bipin N Savani; Mary E D Flowers; Bronwen E Shaw; Nuria Valdés-Sanz Journal: Biol Blood Marrow Transplant Date: 2018-12-03 Impact factor: 5.742
Authors: Joseph R Abraham; Charles C Wykoff; Sruthi Arepalli; Leina Lunasco; Hannah J Yu; Alison Martin; Christopher Mugnaini; Ming Hu; Jamie Reese; Sunil K Srivastava; David M Brown; Justis P Ehlers Journal: Br J Ophthalmol Date: 2021-06-07 Impact factor: 5.908